ATAXIA TELANGIECTASIA
Clinical trials for ATAXIA TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new ATAXIA TELANGIECTASIA trials appear
Sign up with your email to follow new studies for ATAXIA TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Continued EryDex treatment studied in rare neurological disorder
Disease control TerminatedThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control TerminatedThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC